Disappointment for Australian company Actinogen Medical (ASX:ACW) with the release of data from its phase 2 clinical trial (XanADu) investigating its investigative therapy Xanamem in patients with mild dementia due to Alzheimer’s disease. …
Latest Video
New Stories
-
Nominations open against a backdrop of change
September 16, 2019 - - Latest News -
Medicines Australia moves to broaden product focus
September 16, 2019 - - Latest News -
Venture capital leader warns against impact of government claims over research
September 16, 2019 - - Latest News -
Industry watching for the Final Budget Outcome
September 16, 2019 - - Latest News -
Boehringer Ingelheim funded grant for STROKE-AI project
September 16, 2019 - - Latest News -
Biotech leaders in Canberra to promote R&D investment
September 13, 2019 - - Latest News -
Industry 'hackles' over compassionate access pressure
September 13, 2019 - - Latest News